Jensen R, Brinck T, Olesen J
Department of Neurology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Neurology. 1994 Apr;44(4):647-51. doi: 10.1212/wnl.44.4.647.
We included 43 patients with migraine without aura in a triple-blind, placebo- and dose-controlled, crossover study of the prophylactic effect of slow-release sodium valproate; 34 patients completed the trial. The number of days with migraine was 3.5 per 4 weeks during treatment with sodium valproate and 6.1 during placebo (p = 0.002). The severity and duration of the migraine attacks that did occur were not affected by sodium valproate when compared with placebo. Fifty percent of the patients were responders, ie, their initial migraine frequency was reduced to 50% or less during sodium valproate as compared with 18% during placebo. The number of responders increased during the trial to 65% in the last 4 weeks of the active treatment period. There were no serious side effects requiring withdrawal of patients from the study. We conclude that sodium valproate is an effective and well-tolerated prophylactic medication for migraine without aura.
我们将43例无先兆偏头痛患者纳入一项关于缓释丙戊酸钠预防效果的三盲、安慰剂和剂量对照、交叉研究；34例患者完成了试验。丙戊酸钠治疗期间每4周偏头痛天数为3.5天，安慰剂治疗期间为6.1天（p = 0.002）。与安慰剂相比，确实发生的偏头痛发作的严重程度和持续时间不受丙戊酸钠影响。50%的患者有反应，即与安慰剂治疗期间的18%相比，他们在丙戊酸钠治疗期间最初的偏头痛频率降低到50%或更低。在试验期间，在积极治疗期的最后4周，有反应者的比例增加到65%。没有严重副作用导致患者退出研究。我们得出结论，丙戊酸钠是一种有效且耐受性良好的无先兆偏头痛预防性药物。
